Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras

Plant Biotechnology Journal

Volumn 11, Issue 8, 2013, Pages 964-975

  Pineo, Catherine B ^a   Hitzeroth, Inga I ^a   Rybicki, Edward P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cross protection; HPV 16; L1 L2 chimaera; Plant expression; Vaccine

Indexed keywords

AGROBACTERIUM; CHIMAERIFORMES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; MIRIDAE; MUS; NICOTIANA BENTHAMIANA; NICOTIANA OBTUSIFOLIA; NICOTIANA TABACUM; PAPILLOMAVIRIDAE; RHIZOBIUM;

CAPSID PROTEIN; HYBRID PROTEIN; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VACCINE; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

AGROBACTERIUM; ARTICLE; BIOSYNTHESIS; CROSS-PROTECTION; GENETICS; HPV-16; IMMUNOLOGY; L1/L2 CHIMAERA; METABOLISM; PLANT EXPRESSION; SERODIAGNOSIS; TOBACCO; TRANSGENIC PLANT;

CROSS-PROTECTION; HPV-16; L1/L2 CHIMAERA; PLANT EXPRESSION; VACCINE;

AGROBACTERIUM; ANTIGENS, VIRAL; CAPSID PROTEINS; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; PLANTS, GENETICALLY MODIFIED; RECOMBINANT FUSION PROTEINS; TOBACCO; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84884413506     PISSN: 14677644     EISSN: 14677652     Source Type: Journal    
DOI: 10.1111/pbi.12089     Document Type: Article

References (80)

1. Allan, B., Marais, D.J., Hoffman, M., Shapiro, S. and Williamson, A.L. (2008) Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J. Clin. Microbiol. 46, 740-742.
2. Alphs, H.H., Gambhira, R., Karanam, B., Roberts, J.N., Jagu, S., Schiller, J.T., Zeng, W., Jackson, D.C. and Roden, R.B. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl Acad. Sci. USA, 105, 5850-5855.
3. Baek, J.O., Seo, J.W., Kim, I.H. and Kim, C.H. (2011) Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography. Protein Expr. Purif. 75, 211-217.
4. Bazan, S.B., de Alencar Muniz Chaves, A., Aires, K.A., Cianciarullo, A.M., Garcea, R.L. and Ho, P.L. (2009) Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch. Virol. 154, 1609-1617.
5. Biemelt, S., Sonnewald, U., Galmbacher, P., Willmitzer, L. and Müller, M. (2003) Production of human papillomavirus type 16 virus-like particles in transgenic plants. J. Virol. 77, 9211-9220.
6. Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119, 445-462.
7. Buck, C.B., Cheng, N., Thompson, C.D., Lowy, D.R., Steven, A.C., Schiller, J.T. and Trus, B.L. (2008) Arrangement of L2 within the papillomavirus capsid. J. Virol. 82, 5190-5197.
8. Christensen, N.D. and Kreider, J.W. (1990) Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64, 3151-3156.
9. Christensen, N.D., Dillner, J., Eklund, C., Carter, J.J., Wipf, G.C., Reed, C.A., Cladel, N.M. and Galloway, D.A. (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology, 223, 174-184.
10. Clifford, G.M., Smith, J.S., Plummer, M., Muñoz, N. and Franceschi, S. (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer, 88, 63-73.
11. Collier, B., Oberg, D., Zhao, X. and Schwartz, S. (2002) Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J. Virol. 76, 2739-2752.
12. Duvenage, L., Hitzeroth, I.I., Meyers, A.E. and Rybicki, E.P. (2013) Expression in tobacco and purification of beak and feather disease virus capsid protein fused to elastin-like polypeptides. J. Virol. Methods, 191, 55-62.
13. Embers, M.E., Budgeon, L.R., Pickel, M. and Christensen, N.D. (2002) Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 76, 9798-9805.
14. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127, 2893-2917.
15. Fernández-San Millán, A., Ortigosa, S.M., Hervás-Stubbs, S., Corral-Martínez, P., Seguí-Simarro, J.M., Gaétan, J., Coursaget, P. and Veramendi, J. (2008) Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J. 6, 427-441.
16. Fischer, R., Stoger, E., Schillberg, S., Christou, P. and Twyman, R.M. (2004) Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 7, 152-158.
17. Fleury, M.J., Touzé, A., Maurel, M.C., Moreau, T. and Coursaget, P. (2009) Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci. 18, 1425-1438.
18. Fligge, C., Giroglou, T., Streeck, R.E. and Sapp, M. (2001) Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology, 283, 353-357.
19. Future, II Study Group. (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927.
20. Gambhira, R., Gravitt, P.E., Bossis, I., Stern, P.L., Viscidi, R.P. and Roden, R.B. (2006) Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res. 66, 11120-11124.
21. Gambhira, R., Jagu, S., Karanam, B., Gravitt, P.E., Culp, T.D., Christensen, N.D. and Roden, R.B. (2007a) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 81, 11585-11592.
22. Gambhira, R., Karanam, B., Jagu, S., Roberts, J.N., Buck, C.B., Bossis, I., Alphs, H., Culp, T., Christensen, N.D. and Roden, R.B. (2007b) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81, 13927-13931.
23. Giorgi, C., Franconi, R. and Rybicki, E.P. (2010) Human Papillomavirus vaccines in plants. Expert Rev. Vaccines, 9, 913-924.
24. Giroglou, T., Florin, L., Schäfer, F., Streeck, R.E. and Sapp, M. (2001) Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75, 1565-1570.
25. zur Hausen, H. (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92, 690-698.
26. zur Hausen, H., de Villiers, E.M. and Gissmann, L. (1981) Papillomavirus infections and human genital cancer. Gynecol. Oncol. 12, S124-S128.
27. Jagu, S., Kwak, K., Garcea, R.L. and Roden, R.B. (2010) Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine, 28, 4478-4486.
28. Kawana, K., Matsumoto, K., Yoshikawa, H., Taketani, Y., Kawana, T., Yoshiike, K. and Kanda, T. (1998) A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology, 245, 353-359.
29. Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K. and Kanda, T. (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. 73, 6188-6190.
30. Kawana, K., Kawana, Y., Yoshikawa, H., Taketani, Y., Yoshiike, K. and Kanda, T. (2001) Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine, 19, 1496-1502.
31. Kawana, K., Yasugi, T., Kanda, T., Kino, N., Oda, K., Okada, S., Kawana, Y., Nei, T., Takada, T., Toyoshima, S., Tsuchiya, A., Kondo, K., Yoshikawa, H., Tsutsumi, O. and Taketani, Y. (2003) Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV-16 L2 administered nasally in healthy volunteers. Vaccine, 21, 4256-4260.
32. Kim, H.J., Kim, S.Y., Lim, S.J., Kim, J.Y., Lee, S.J. and Kim, H.J. (2010) One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr. Purif. 70, 68-74.
33. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D.R. and Schiller, J.T. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA, 89, 12180-12184.
34. Koh, Y.T., Higgins, S.A., Weber, J.S. and Kast, W.M. (2006) Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J. Transl. Med. 4: 42. doi:10.1186/1479-5876-4-42.
35. Kohl, T., Hitzeroth, I.I., Stewart, D., Varsani, A., Govan, V.A., Christensen, N.D., Williamson, A.L. and Rybicki, E.P. (2006) Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin. Vaccine Immunol. 13, 845-853.
36. Kondo, K., Ishii, Y., Ochi, H., Matsumoto, T., Yoshikawa, H. and Kanda, T. (2007) Neutralization of HPV-16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV-16 minor capsid protein L2 surface region. Virology, 358, 266-272.
37. Kondo, K., Ochi, H., Matsumoto, T., Yoshikawa, H. and Kanda, T. (2008) Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J. Med. Virol. 80, 841-846.
38. Lenzi, P., Scotti, N., Alagna, F., Tornesello, M.L., Pompa, A., Vitale, A., De Stradis, A., Monti, L., Grillo, S., Buonaguro, F.M., Maliga, P. and Cardi, T. (2008) Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res. 17, 1091-1102.
39. Li, M., Beard, P., Estes, P.A., Lyon, M.K. and Garcea, R.L. (1998) Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J. Virol. 72, 2160-2167.
40. Li, N., Franceschi, S., Howell-Jones, R., Snijders, P.J. and Clifford, G.M. (2011) Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer, 128, 927-935.
41. Lin, K., Doolan, K., Hung, C.F. and Wu, T.C. (2010) Perspectives for preventive and therapeutic HPV vaccines. J. Formos. Med. Assoc. 109, 4-24.
42. Liu, H.L., Li, W.S., Lei, T., Zheng, J., Zhang, Z., Yan, X.F., Wang, Z.Z., Wang, Y.L. and Si, L.S. (2005) Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim. Biophys. Sin. (Shanghai) 37, 153-158.
43. Maclean, J., Koekemoer, M., Olivier, A.J., Stewart, D., Hitzeroth, I.I., Rademacher, T., Fischer, R., Williamson, A.L. and Rybicki, E.P. (2007) Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol. 88, 1460-1469.
44. Matić, S., Rinaldi, R., Masenga, V. and Noris, E. (2011) Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol. 11: 106. doi: 10.1186/1472-6750-11-106.
45. McCarthy, M.P., White, W.I., Palmer-Hill, F., Koenig, S. and Suzich, J.A. (1998) Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. J. Virol. 72, 32-41.
46. McGrath, M., de Villiers, G.K., Shephard, E., Hitzeroth, I.I. and Rybicki, E.P. (2013) Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Arch. Virol. 158: 5 doi: 10.1007/s00705-013-1713-8.
47. McLean, C.S., Churcher, M.J., Meinke, J., Smith, G.L., Higgins, G., Stanley, M. and Minson, A.C. (1990) Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J. Clin. Pathol. 43, 488-492.
48. Modis, Y., Trus, B.L. and Harrison, S.C. (2002) Atomic model of the papillomavirus capsid. EMBO J. 21, 4754-4762.
49. Münger, K., Baldwin, A., Edwards, K.M., Hayakawa, H., Nguyen, C.L., Owens, M., Grace, M. and Huh, K. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451-11460.
50. Muñoz, N., Bosch, F.X., Castellsagué, X., Diaz, M., de Sanjosé, S., Hammouda, D., Shah, K.V. and Meijer, C.J.L.M. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int. J. Cancer, 111, 278-285.
51. Murata, Y., Lightfoote, P.M., Rose, R.C. and Walsh, E.E. (2009) Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol. J. 6: 81. doi: 10.1186/1743-422X-6-81.
52. Ohlschläger, P., Osen, W., Dell, K., Faath, S., Garcea, R.L., Jochmus, I., Müller, M., Pawlita, M., Schäfer, K., Sehr, P., Staib, C., Sutter, G. and Gissmann, L. (2003) Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol. 77, 4635-4645.
53. Parkin, D.M. and Bray, F. (2006) Chapter 2: The burden of HPV-related cancers. Vaccine, 24, S3/11-25.
54. Paz De la Rosa, G., Monroy-García, A., Mora-García Mde, L., Peña, C.G., Hernández-Montes, J., Weiss-Steider, B. and Gómez-Lim, M.A. (2009) An HPV-16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol. J. 6: 2. doi: 10.1186/1743-422X-6-2.
55. Regnard, G.L., Halley-Stott, R.P., Tanzer, F.L., Hitzeroth, I.I. and Rybicki, E.P. (2010) High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol. J. 8, 38-46.
56. Roden, R.B., Yutzy, W.H. 4th, Fallon, R., Inglis, S., Lowy, D.R. and Schiller, J.T. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology, 270, 254-257.
57. Rommel, O., Dillner, J., Fligge, C., Bergsdorf, C., Wang, X., Selinka, H.C. and Sapp, M. (2005) Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J. Med. Virol. 75, 114-121.
58. Rose, R.C., Bonnez, W., Da Rin, C., McCance, D.J. and Reichman, R.C. (1994) Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J. Gen. Virol. 75, 2445-2449.
59. Rose, R.C., White, W.I., Li, M., Suzich, J.A., Lane, C. and Garcea, R.L. (1998) Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J. Virol. 72, 6151-6154.
60. Rubio, I., Bolchi, A., Moretto, N., Canali, E., Gissmann, L., Tommasino, M., Müller, M. and Ottonello, S. (2009) Potent anti-HPV immune responses induced by tandem repeats of the HPV-16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine, 27, 1949-1956.
61. Rybicki, E.P. (2009) Plant-produced vaccines: promise and reality. Drug Discov. Today, 14, 16-24.
62. Rybicki, E.P. (2010) Plant-made vaccines for humans and animals. Plant Biotechnol. J. 8, 620-637.
63. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
64. de Sanjosé, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., Tous, S., Felix, A., Bravo, L.E., Shin, H.R., Vallejos, C.S., de Ruiz, P.A., Lima, M.A., Guimera, N., Clavero, O., Alejo, M., Llombart-Bosch, A., Cheng-Yang, C., Tatti, S.A., Kasamatsu, E., Iljazovic, E., Odida, M., Prado, R., Seoud, M., Grce, M., Usubutun, A., Jain, A., Suarez, G.A., Lombardi, L.E., Banjo, A., Menéndez, C., Domingo, E.J., Velasco, J., Nessa, A., Chichareon, S.C., Qiao, Y.L., Lerma, E., Garland, S.M., Sasagawa, T., Ferrera, A., Hammouda, D., Mariani, L., Pelayo, A., Steiner, I., Oliva, E., Meijer, C.J., Al-Jassar, W.F., Cruz, E., Wright, T.C., Puras, A., Llave, C.L., Tzardi, M., Agorastos, T., Garcia-Barriola, V., Clavel, C., Ordi, J., Andújar, M., Castellsagué, X., Sánchez, G.I., Nowakowski, A.M., Bornstein, J., Muñoz, N. and Bosch, F.X.; Retrospective International Survey and HPV Time Trends Study Group (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048-1056.
65. Sapp, M., Fligge, C., Petzak, I., Harris, J.R. and Streeck, R.E. (1998) Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J. Virol. 72, 6186-6189.
66. Schädlich, L., Senger, T., Gerlach, B., Mücke, N., Klein, C., Bravo, I.G., Müller, M. and Gissmann, L. (2009) Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J. Virol. 83, 7690-7705.
67. Schellenbacher, C., Roden, R. and Kirnbauer, R. (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 83, 10085-10095.
68. Schiller, J.T., Castellsagué, X., Villa, L.L. and Hildesheim, A. (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine, 26, K53-K61.
69. Slupetzky, K., Shafti-Keramat, S., Lenz, P., Brandt, S., Grassauer, A., Sara, M. and Kirnbauer, R. (2001) Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J. Gen. Virol. 82, 2799-2804.
70. Slupetzky, K., Gambhira, R., Culp, T.D., Shafti-Keramat, S., Schellenbacher, C., Christensen, N.D., Roden, R.B. and Kirnbauer, R. (2007) A papillomavirus-like particle (VLP) vaccine displaying HP V-16 L2 epitopes induces cross-neutralizing antibodies to HPV-11. Vaccine, 25, 2001-2010.
71. Smith, J.S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R. and Clifford, G.M. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer, 121, 621-632.
72. Studentsov, Y.Y., Schiffman, M., Strickler, H.D., Ho, G.Y., Pang, Y.Y., Schiller, J., Herrero, R. and Burk, R.D. (2002) Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J. Clin. Microbiol. 40, 1755-1760.
73. Sullivan, C.S. and Pipas, J.M. (2001) The virus-chaperone connection. Virology, 287, 1-8.
74. Takeda, A., Sugiyama, K., Nagano, H., Mori, M., Kaido, M., Mise, K., Tsuda, S. and Okuno, T. (2002) Identification of a novel RNA silencing suppressor, NSs protein of Tomato spotted wilt virus. FEBS Lett. 532, 75-79.
75. Thönes, N., Herreiner, A., Schädlich, L., Piuko, K. and Müller, M. (2008) A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than virus-like particles with respect to the induced antibody response. J. Virol. 82, 5472-5485.
76. Varsani, A., Williamson, A.L., de Villiers, D., Becker, I., Christensen, N.D. and Rybicki, E.P. (2003a) Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J. Virol. 77, 8386-8393.
77. Varsani, A., Williamson, A.L., Rose, R.C., Jaffer, M. and Rybicki, E.P. (2003b) Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol. 148, 1771-1786.
78. Varsani, A., Williamson, A.L., Stewart, D. and Rybicki, E.P. (2006a) Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res. 120, 91-96.
79. Varsani, A., Williamson, A.L., Jaffer, M.A. and Rybicki, E.P. (2006b) A deletion and point mutation study of the human papillomavirus type 16 major capsid gene. Virus Res. 122, 154-163.
80. Yuan, H., Estes, P.A., Chen, Y., Newsome, J., Olcese, V.A., Garcea, R.L. and Schlegel, R. (2001) Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol. 75, 7848-7853.